Vasculature, Biomarkers and the Matrix of Hypertensive Heart Disease

Valeriya Nemtsova,Annina S. Vischer,Thilo Burkard

DOI: https://doi.org/10.3390/jcm13020505

IF: 3.9

2024-01-17

Journal of Clinical Medicine

Abstract:Over the last few decades, research efforts have resulted in major advances in our understanding of the pathophysiology of hypertensive heart disease (HHD). This is the third part of a three-part review series. Here, we focus on the influence of high blood pressure on the micro- and macroalterations that occur in the vasculature in HHD. We also provide an overview of circulating cardiac biomarkers that may prove useful for a better understanding of the pathophysiology, development and progression of HHD, and may play a unique role in the diagnostic and prognostic evaluation of patients with HHD, taking into account their properties showing as abnormal long before the onset of the disease. In the conclusion, we propose an updated definition of HHD and a matrix for clinical classification, which we suspect will be useful in practice, allowing an individual approach to HHD patients.

medicine, general & internal

What problem does this paper attempt to address?

### Problems the Paper Aims to Address

This paper aims to explore the vascular pathological changes in hypertensive heart disease (HHD) and its related biomarkers, and proposes an updated definition and clinical classification matrix. Specifically:

1. **Vascular Pathological Changes**: The paper discusses in detail the impact of hypertension on microvascular and macrovascular structures, including vascular remodeling, arterial stiffness, and increased peripheral vascular resistance, and explores the role of these changes in hypertensive heart disease.

2. **Biomarkers**: The paper also reviews the application value of circulating cardiac biomarkers in hypertensive heart disease, especially those that may help in early diagnosis, assessment of disease progression, and prognosis. For example, N-terminal pro-brain natriuretic peptide (NT-proBNP) is highlighted as a potential biomarker.

3. **Clinical Classification Matrix**: Finally, the authors propose an updated definition and clinical classification matrix for hypertensive heart disease, aiming to provide more precise guidance for clinical practice and avoid incomplete assessment of different phenotypes of patients.

In summary, the goal of this paper is to comprehensively understand the pathophysiological mechanisms of hypertensive heart disease and to provide new tools and methods for clinical diagnosis and treatment.